Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

2015 BioMedTracker Pre-ASH Report

1,421 views

Published on

  • I was searching for a way to explain my recently frequent yeast infections and other related conditions stumbled upon your program on the internet. I suffered from chronic mouth thrush (with creamy white lesions on my tongue and inner cheeks). My baby daughter had the same problem in her mouth and your program was the only thing that helped us! I highly recommend your book to anyone who is perceptive about their health, and for those who are tired of being told that it's all in their heads. I feel so rejuvenated and lucky to have found this system.  http://scamcb.com/index7/pdf
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Improve your Kidney Health Naturally, click here to find out how ◆◆◆ https://tinyurl.com/yy8pd5uf
       Reply 
    Are you sure you want to  Yes  No
    Your message goes here
  • Be the first to like this

2015 BioMedTracker Pre-ASH Report

  1. 1. 2015 Pre-ASH Report QUESTIONS? EMAIL BIOMEDSUBSCRIBE@SAGIENTRESEARCH.COM FOR OUR DISCLOSURES, PLEASE SEE BIOMEDTRACKER’s RESEARCH STANDARDS 1 2015 W W W. B I O M E D T R AC K E R . C O M BioMedTracker Pre-ASH Report American Society of Hematology Annual Meeting Orlando, FL | December 5-8, 2015
  2. 2. 2015 Pre-ASH Report QUESTIONS? EMAIL BIOMEDSUBSCRIBE@SAGIENTRESEARCH.COM FOR OUR DISCLOSURES, PLEASE SEE BIOMEDTRACKER’s RESEARCH STANDARDS 2 Summary The 57th Annual Meeting of the American Society of Hematology (ASH) will be held in Orlando, FL from December 5-8, 2015. We have assembled a pre-meeting listing of highlights based on presentation titles and abstracts that were released. We have also included a full, easy-to-read meeting planner detailing the presentations and posters scheduled for each day of the ASH meeting. Conference Highlights  Profiled themes in the 2015 ASH Agenda include: Genomic Profiling and Chemical Biology, Genome Editing and Gene Therapy, Epigenetic Mechanisms, Immunologic Treatments, Stem Cell Biology and Regenerative Medicine and Preventing Venous Thromboembolic Disease  Venetoclax for CLL (ABBV). Results will be presented for the pivotal Phase II M13-982 trial of venetoclax monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia (CLL) with a 17p deletion (#LBA-6). Venetoclax, a BCL-2 inhibitor, was granted Breakthrough Therapy Designation by the FDA in May 2015.  KTE-C19 for NHL (KITE). Top-line results will be presented from the Phase I portion of the ZUMA- 1 trial with KTE-C19 in patients with refractory, aggressive non-Hodgkin’s lymphoma (NHL) including DLBCL, PMBCL and TFL (#3991). The CAR-T therapy KTE-C19 was first granted Orphan Drug designation for treatment of DLBCL in Mar 2014 by the FDA.  Zydelig for CLL (GILD). Top-line results will be presented from the Phase III 115 trial of Zydelig (idelalisib) plus bendamustine and rituximab (BR) in patients with refractory/relapsed CLL. An interim analysis demonstrated that idelalisib, a PI3K delta inhibitor, in combination with BR was superior to BR alone for PFS and OS, key primary and secondary endpoints (#LBA-5).  Ninlaro for Multiple Myeloma (Takeda). Data from the Phase III TOURMALINE-MM1 trial of the once-weekly oral proteasome inhibitor Ninlaro (ixazomib) in combination with Revlimid (lenalidomide) and dexamethasone in relapsed/refractory (R/R) multiple myeloma (MM) will be presented (#727). Takeda announced that this trial met its primary endpoint of improving PFS in February 2015 and data from the trial have recently supported the drug’s approval for treatment of R/R MM. This is the first presentation of Phase III data for Ninlaro in MM, and should give some idea as to whether Ninlaro will be able to compete with the approved proteasome inhibitors Velcade (bortezomib) and Kyprolis (carfilzomib).  Keytruda for CLL (MRK). Merck & Co. will showcase the first clinical trial data for a programmed death-1 receptor (PD-1) inhibitor in CLL (#834). In a Phase II trial (MC1485), Keytruda (permbrolizumab) was well-tolerated and showed promising efficacy in heavily pre-treated R/R CLL patients, including patients with Richter’s Transformation.  Imbruvica for CLL (ABBV/JNJ). The results of the Phase III RESONATE-2 trial of Imbruvica (ibrutinib) monotherapy versus chlorambucil monotherpay in previously untreated elderly (≥65) CLL patients will be presented (#495). Imbruvica is already approved for treatment of R/R and
  3. 3. 2015 Pre-ASH Report QUESTIONS? EMAIL BIOMEDSUBSCRIBE@SAGIENTRESEARCH.COM FOR OUR DISCLOSURES, PLEASE SEE BIOMEDTRACKER’s RESEARCH STANDARDS 3 high-risk (17p-deletion) CLL, and an sNDA was filed in September 2015 to expand its use to first- line therapy based on RESONATE-2 data. AbbVie announced in June that the RESONATE-2 trial achieved its primary endpoint and multiple secondary endpoints, and now we are seeing for the first time strong response rates, PFS, and OS data that will justify the drug’s approval and provide a valuable first-line option for elderly CLL patients.  CTL019 for ALL (NVS/ University of Pennsylvania). On Monday afternoon, Novartis/University of Pennsylvania will report on an interesting and potentially important development to their CAR-T program in (#683). The first data from a Phase I study of humanized CD-19-directed CAR T cells (dubbed CTL119) in pediatric ALL patients who previously received the standard murine- based CTL019 will be presented, and theories relating to immune-mediated rejection of murine- based CTL019 and how to overcome this problem to improve remission rats will be discussed.  First-in-class clinical results include: AG-120, a mutant IDH1 inhibitor (#1306), cirmtuzumab, an anti-ROR1 monoclonal antibody (#1736), Selinexor, an XPO1 inhibitor (#258), CB-839, a glutaminase inhibitor (#2566), AG-221, a mutant IDH2 inhibitor (#2509), vosaroxin, a quinolone- derived DNA intercalator and topoisomerase II inhibitor (#461), sotatercept, an activin type IIA receptor fusion protein (#4241) and ricolinostat, a HDAC6 selective inhibitor (#3040).
  4. 4. Session Name: Friday Scientific Workshop on Hematology and Aging Session Location: Tangerine 2 (WF2) (Orange County Convention Center) Session Time: 1:00pm-6:00pm Start Time End Time Presentation Title Company Drug Presenter Presentation ID 1:00 PM 6:00 PM Inherited Bmf Syndromes Presenting in Older Adults Jane Churpek 1:00 PM 6:00 PM Telomere Dysfunction and Senescence in Marrow Failure Syndrome Rodrigo Calado 1:00 PM 6:00 PM Erythroid Progenitor Cell Differentiation in Normal Elderly and in Unexplained Anemia Wendy Pang 1:00 PM 6:00 PM Cytopenias and Clonal Hematopoiesis of Indeterminate Potential Rafael Bejar 1:00 PM 6:00 PM Nutritional Impairment in Hematologic Malignancies, Impact on Outcomes Reinhard Stauder 1:00 PM 6:00 PM Markers of Frailty and Survival in MDS Rena Buckstein 1:00 PM 6:00 PM Use of Geriatric Assessment to Predict Toxicities and Survival in Multiple Myeloma Sara Bringhen 1:00 PM 6:00 PM Biologic Correlates of Frailty in Stem Cell Transplantation Andrew Artz 1:00 PM 6:00 PM BTK Inhibitors in Older Adults with CLL- Resistance Patterns and Correlation with Toxicity Jennifer Woyach 1:00 PM 6:00 PM Demethylation to Reverse Age-Related Stem Cell Senescence Nadim Mahmud 1:00 PM 6:00 PM Monoclonal Gammopathy in Older Adults Irene Ghobrial 1:00 PM 6:00 PM Cellular Senescence and Aging Ashley Rosko Session Name: Friday Scientific Workshop on Myeloid Development Session Location: Tangerine 1 (WF1) (Orange County Convention Center) Session Time: 1:00pm-6:00pm Start Time End Time Presentation Title Company Drug Presenter Presentation ID 1:00 PM 6:00 PM A Novel MLL-AF4 In Vivo Model Phenocopies t(4;11) Pro-B ALL and Reveals a Lymphoid Lineage Bias of the Fusion Protein in Human Cells Michael Thirman 1:00 PM 6:00 PM Rpl22 Deficiency Predisposes Hematopoietic Stem and Progenitor Cells to Leukemogenesis David Wiest 1:00 PM 6:00 PM LNK(SH2B3) Signaling in Normal and Malignant B-Progenitors Wei Tong 1:00 PM 6:00 PM Interleukin-1 Drives Precocious Myeloid Differentiation of Hematopoietic Stem Cells at the Expense of Self-Renewal Eric Pietras 1:00 PM 6:00 PM Functional Proteomics of Acute Myeloid Leukemia Alex Kentsis 1:00 PM 6:00 PM LMO2 Regulates DNA Replication in Hematopoietic Cells Trang Hoang 1:00 PM 6:00 PM AURKA Restricts Megakaryocytic Differentiation By Phosphorylation of NFE2: Implications for MPN Therapies John Crispino 1:00 PM 6:00 PM High Mobility Group A1 Chromatin Remodeling Protein Drives Self-Renewal, Niche Formation, and Regenerative Function in Adult Stem Cells through Wnt/β-Catenin Signaling and SOX9 Linda Resar 1:00 PM 6:00 PM The LRF/ZBTB7A Transcription Factor Regulates BCL11A-Independent Globin Switching Takahiro Maeda 1:00 PM 6:00 PM Beyond FLT3: Recurrent Mutations in CCND3 Confer Resistance to FLT3 Inhibition in AML Catherine Smith 1:00 PM 6:00 PM Integrative Genome-Wide Analysis of RNA Binding and Splicing By Mutant SRSF2 Stephanie Halene 1:00 PM 6:00 PM HIF-1α Signaling Is a Central Pathobiologic Mediator of Myelodysplastic Syndromes Gang Huang 1:00 PM 6:00 PM Cytokine-Mediated Differentiation Reflects Genome-Wide Loss of a Ustat Transcriptional Program Anthony Green 1:00 PM 6:00 PM Regulation of the MLL Complex and H3K4me3 By Son and Its Isoforms Eun-Young Erin Ahn 1:00 PM 6:00 PM Monocyte Lineages in the Bone Marrow Frederic Geissmann 1:00 PM 6:00 PM Modeling Leukemia Progression with Patient-Derived iPSCs Eirini Papapetrou 1:00 PM 6:00 PM Regulation of Neutrophil Lifespan and NET Release By Mlkl Ben Croker 1:00 PM 6:00 PM Serotonin and HSC Production Trista North 1:00 PM 6:00 PM Notch Regulation of Enhancer Function Determines Drug Resistance in Leukemia Warren Pear 1:00 PM 6:00 PM Inflammation-Induced Emergency Megakaryopoiesis Driven By Hematopoietic Stem Cell-like Megakaryocyte Progenitors Marieke Essers 1:00 PM 6:00 PM Hematopoietic Stem Cell Loss after Chronic Infection Katherine King 1:00 PM 6:00 PM Thrombopoietin but Not G-CSF Receptor Stimulation Induces Self-Renewing Hematopoietic Stem Cell Divisions In Vivo Markus Manz 1:00 PM 6:00 PM Pulse-Mediated Circumferential Stretch Stimulates Hematopoietic Stem Cell Formation Dhvanit Shah 1:00 PM 6:00 PM Loss of Crebbp Confers Pre-Lymphoma/Lymphoma Stem Cell Properties on Lymphoid Progenitor Brian Huntly 1:00 PM 6:00 PM Polycomb Repressive Complex 1 Enhances HSC Self-Renewal through Repressing the Canonical Wnt Signaling Pathway Yan Liu Session Name: American Board of Internal Medicine Maintenance of Certification Learning Session Session Location: Regency Ballroom O-P (Hyatt Regency Orlando) Session Time: 2:00pm-5:00pm Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 5:00 PM Coagulation/Platelet/Hemostasis Alice Ma 2:00 PM 5:00 PM Leukemia/Stem Cell Transplant Christian Cable 2:00 PM 5:00 PM Hematologic Malignancy (Myeloma, Lymphoma, CLL) James W. Lynch 2015 BioMedTracker ASH Planner Friday December 4- Oral Presentations
  5. 5. Session Name: 311. Disorders of Platelet Number or Function: Immune Thrombocytopenia and Platelet Survival Session Location: W315 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Determine the Safety and Efficacy of Romiplostim in Children with Immune Thrombocytopenia (ITP) Amgen Nplate Michael Tarantino 7 7:30 AM 9:00 AM Splenic and Circulating Human T Follicular Helper Cell Regulation By B Cell Depleting Therapy during Immune Thrombocytopenia Sylvain Audia 8 7:30 AM 9:00 AM Serious and Non-Serious Infections in Non-Splenectomized Adults Treated for Persistent or Chronic Primary Immune Thrombocytopenia: Effect of Treatments and Protection of Vaccines. Results of the French Nationwide Faith Study Guillaume Moulis 9 7:30 AM 9:00 AM A Humanized Anti Fcγriia Scfv Inhibits Platelet Activation, Aggregation and Thrombus Formation in Heparin-Induced Thrombocytopenia (HIT) Beng Chong 10 7:30 AM 9:00 AM Regulation of Platelet Lifespan in the Presence and Absence of TPO Signaling Emma Josefsson 11 7:30 AM 9:00 AM Platelet GPIba Is Important for Thrombopoietin Production and Thrombopoietin-Induced Platelet Generation Miao Xu 12 Session Name: 631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: CML – Mechanisms of Disease Progression and Leukemic Stem Cell Persistence Session Location: W340 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Single Cell Whole Transcriptome Analysis Reveals Distinct Molecular Signatures of Therapy- Resistant Chronic Myeloid Leukemia Stem Cells Alice Giustacchini 13 7:30 AM 9:00 AM MS4A3 Improves Imatinib Response and Survival in BCR-ABL1 Primary TKI Resistance and in Blastic Transformation of Chronic Myeloid Leukemia Anna Eiring 14 7:30 AM 9:00 AM A Novel TNF-Alpha Antibody Based Therapeutic Approach to Target Leukemic Stem Cells in Bcr-Abl Disease Mirle Schemionek 15 7:30 AM 9:00 AM Beclin-1 Phosphorylation By BCR-ABL Is Crucial for CML Leukemogenesis By Suppression of Autophagy Chuanjiang Yu 16 7:30 AM 9:00 AM Identification of TKI-Sensitive Point Mutations That Activate c-ABL Kinase Activity and Transformation Potential and Confer in Vitro Resistance to the Allosteric ABL Inhibitor GNF-5 Bianca Lee 17 7:30 AM 9:00 AM Chronic Myeloid Leukemia Patients with Deep Molecular Responses to Tyrosine Kinase Inhibitors Have Increased Effector Natural Killer and Cytotoxic T Cell Immune Responses to Leukaemia- Associated Antigens and Concomitant Reduced Immune Suppressors Amy Hughes 18 Session Name: 651. Myeloma: Biology and Pathophysiology, excluding Therapy: Revealing Subclonal Heterogeneity in Multiple Myeloma Session Location: Tangerine 1 (WF1) (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Prognostic Value of Antigen Expression in Multiple Myeloma (MM): A Large GEM/Pethema Study Based in Four Consecutive Clinical Trials Bruno Paiva 19 7:30 AM 9:00 AM High Risk Multiple Myeloma Demonstrates Marked Spatial Genomic Heterogeneity Between Focal Lesions and Random Bone Marrow; Implications for Targeted Therapy and Treatment Resistance Niels Weinhold 20 7:30 AM 9:00 AM Deep Igh Sequencing Identifies an Ongoing Somatic Hypermutation Process with Complex and Evolving Clonal Architecture in Myeloma Nikhil Munshi 21 7:30 AM 9:00 AM Humanized Mouse Model of Myeloma Reveals Clinically Occult Genomic Changes in Primary Tumor Cells Rakesh Verma 22 7:30 AM 9:00 AM Mutational Profile and Prognostic Relevance of Circulating Tumor Cells in Multiple Myeloma Bruno Paiva 23 7:30 AM 9:00 AM An Amplicon-Targeted Ultra-Deep Sequencing Approach Reveals the Presence at the Onset of Multiple Myeloma and the Selection over Time of TP53 Sub-Clonal Variants, Which Adversely Influence Patients' Overall Survival Carolina Terragna 24 Session Name: 653. Myeloma: Therapy, excluding Transplantation: Advances in Newly Diagnosed and Relapsed Myeloma Session Location: Tangerine 2 (WF2) (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT): Results of the Randomized Phase III Trial SWOG S0777 Celgene Revlimid Brian Durie 25 7:30 AM 9:00 AM Randomized Phase 2 Study of the All-Oral Combination of Investigational Proteasome Inhibitor (PI) Ixazomib Plus Cyclophosphamide and Low-Dose Dexamethasone (ICd) in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Transplant-Ineligible (NCT02046070) Takeda Ninlaro Meletios Dimopoulos 26 7:30 AM 9:00 AM Bortezomib Induction and Maintenance in Patients with Newly Diagnosed Multiple Myeloma: Long- Term Follow-up of the HOVON-65/GMMG-HD4 Trial Takeda Velcade Pieter Sonneveld 27 7:30 AM 9:00 AM Eloquent-2 Update: A Phase 3, Randomized, Open-Label Study of Elotuzumab in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed/Refractory Multiple Myeloma - 3-Year Safety and Efficacy Follow-up Bristol-Myers Squibb Elotuzumab Meletios Dimopoulos 28 7:30 AM 9:00 AM Clinical Efficacy of Daratumumab Monotherapy in Patients with Heavily Pretreated Relapsed or Refractory Multiple Myeloma Johnson & Johnson Darzalex Saad Usmani 29 7:30 AM 9:00 AM Efficacy and Safety of Carfilzomib and Dexamethasone Vs Bortezomib and Dexamethasone in Patients with Relapsed Multiple Myeloma Based on Cytogenetic Risk Status: Subgroup Analysis from the Phase 3 Study Endeavor (NCT01568866) Amgen Kyprolis Wee-Joo Chng 30 Session Name: 701. Experimental Transplantation: Basic Biology, Engraftment, and Disease Activity Session Location: W414AB (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Oncostatin M Enhances Hematopoietic Stem Cell Homing and Engraftment Hannah Rasmussen 31 7:30 AM 9:00 AM Immunotoxin Enables Non-Genotoxic Conditioning for Hematopoietic Stem Cell Transplantation Rahul Palchaudhuri 32 7:30 AM 9:00 AM EPCR/PAR1 Signaling Navigates Long-Term Repopulating Hematopoietic Stem Cell Bone Marrow Homing to Thrombomodulin-Enriched Blood Vessels Shiri Gur Cohen 33 7:30 AM 9:00 AM Hematopoeitic Stem Cells and Their Progenitors Critically Require Autophagy to Promote Early Engraftment Following Allogeneic Stem Cell Transplantation Katie Lineburg 34 7:30 AM 9:00 AM The Use of Eicosanoids to Enhance Donor Cell Engraftment after in Utero Hematopoietic Cell Transplantation (IUHCT) Matthew Boelig 35 7:30 AM 9:00 AM Ciclopirox Ethanolamine Is a Novel Modifier of Human Hematopoietic Stem Cell Ex Vivo Expansion Mehrnaz Safaee Talkhoncheh 36 2015 BioMedTracker ASH Planner Saturday December 5- Oral Presentations
  6. 6. 2015 BioMedTracker ASH Planner Saturday December 5- Oral Presentations Session Name: 901. Health Services and Outcomes Research – Non-Malignant Conditions: Health Outcomes in Inherited and Acquired Bleeding Disorders Session Location: W230 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Effect of Romiplostim on Health-Related Quality of Life in Children with Immune Thrombocytopenia and Associated Burden in Their Parents: Results from a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Amgen Nplate Susan Mathias 37 7:30 AM 9:00 AM Rate of Bleeding-Rated Episodes (BREs) in Elderly Patients with Primary Immune Thrombocytopenia (ITP): A Population-Based Retrospective Cohort Study Using Medicare 20% Sample Data Shuling Li 38 7:30 AM 9:00 AM Impact of Pain and Functional Impairment in US Adult People with Hemophilia (PWH): Patient- Reported Outcomes and Musculoskeletal Evaluation in the Pain, Functional Impairment, and Quality of Life (P-FiQ) Study Christine Kempton 39 7:30 AM 9:00 AM Numeracy in Patients with Hemophilia Duc Tran 40 7:30 AM 9:00 AM Outcomes of Referrals for Mild and Moderate Thrombocytopenia Charles Schlappi 41 7:30 AM 9:00 AM Content, Utilization and Impact of a Hematology e-Consultation Service Adam Fogel 42 Session Name: Advances in the Understanding and Diagnosis of Myelodysplasia and Bone Marrow Failure Syndromes Session Location: Valencia D (W415D) (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Genetics in Inherited Bone Marrow Failure Disorders Sioban Keel SCI-1 7:30 AM 9:00 AM Megakaryocytic Fate Specification and Maturation Diane Krause SCI-2 7:30 AM 9:00 AM Clonal Diversity and Mutated Genes in Myelodysplastic Syndromes Benjamin Ebert SCI-3 Session Name: Challenging Scenarios in Thrombosis Session Location: W311 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM The Antiphospholipid Syndrome: Still an Enigma Keith McCrae 7:30 AM 9:00 AM Perinatal Thrombosis: Implications for Mother and Neonate Sarah O'Brien 7:30 AM 9:00 AM Mechanical Circulatory Support: Balancing Bleeding and Clotting in High Risk Patients Lisa Baumann Kreuziger Session Name: Clonal Architecture and Hierarchy: Implications for Biology and Translation Session Location: W314 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Clonal Events in Normal Aging Hematopoiesis Lambert Busque SCI-10 7:30 AM 9:00 AM Clonal Evolution of Pre-Leukemic Hematopoietic Stem Cells in Human Acute Myeloid Leukemia Ravi Majeti SCI-11 7:30 AM 9:00 AM Clonal Mutations and Clonal Hierarchy in Pediatric Myeloid Neoplasms Charlotte Niemeyer SCI-12 Session Name: Determinants of Clot Structure: Beyond Fibrin Session Location: W308 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Platelet Activation Gradients During Thrombus Formation Timothy Stalker SCI-13 7:30 AM 9:00 AM Factor XIII and Red Blood Cells in Venous Thrombosis Alisa Wolberg SCI-14 7:30 AM 9:00 AM Contribution of Red Blood Cells and Clot Structure to Thrombosis Robert Ariens SCI-15 Session Name: Genetics vs. Response: What Should Direct Future Therapy of Childhood Acute Lymphoblastic Leukemia? Session Location: Tangerine 3 (WF3-4) (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Disease Response Guiding Therapy in Acute Lymphocytic Leukemia: Pivotal Role of Minimal Residual Disease Michael Pulsipher SCI-34 7:30 AM 9:00 AM Genetics Directing Therapy in Acute Lymphocytic Leukemia: Identifying Risk, Defining Targets Andrea Biondi SCI-35 7:30 AM 9:00 AM Epigenetics Directing Therapy in Acute Lymphocytic Leukemia: Emerging Roles and New Therapies Kathrin Bernt SCI-36 Session Name: Harnessing T Cells in Therapy of Hematologic Malignancy Session Location: W304 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Choice of Better T-cells for Adoptive Immunotherapy Dirk Busch SCI-22 7:30 AM 9:00 AM From T-cell Engineering to CAR therapy: Progress and Prospects Michel Sadelain SCI-23 7:30 AM 9:00 AM Latest in Clinical Application of CAR Cell Therapy for B-cell Malignancy and Transplantation Crystal Mackall SCI-24 Session Name: Management of Challenging Bleeding Complications Session Location: Chapin Theater (W320) (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Bleeding Complications in Immune Thrombocytopenia Donald Arnold 7:30 AM 9:00 AM Acquired Bleeding Disorders in the Elderly Rebecca Kruse-Jarres 7:30 AM 9:00 AM Coagulopathy of Liver Disease Jody Kujovich Session Name: Myeloproliferative Neoplasms: A Clinical Update Session Location: W224 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Management of Symptoms in Polycythemia Vera and Essential Thrombocythemia Deepti Radia 7:30 AM 9:00 AM Looking Forward: Novel Therapeutic Approaches in Chronic and Advanced Phases of Myelofibrosis John Mascarenhas 7:30 AM 9:00 AM Myeloproliferative/Myelodysplastic Overlap Syndromes Eric Padron Session Name: Take a Breath: Heme, Iron, and Cellular Metabolism Session Location: W331 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM The Role of Hepcidin in Health And Disease Martina Muckenthaler SCI-43 7:30 AM 9:00 AM Iron Requirement in Hypoxic Conditions Max Gassmann SCI-44 7:30 AM 9:00 AM Special Delivery: The Role of Iron Chaperones in the Distribution of Iron in Developing Red Cells Caroline Philpott SCI-45
  7. 7. 2015 BioMedTracker ASH Planner Saturday December 5- Oral Presentations Session Name: Targeting the Epigenome Session Location: Hall E1 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Systematic Approaches to Identify Actionable Epigenetic Vulnerabilities in Cancer Christopher Vakoc 7:30 AM 9:00 AM Hierarchical Epigenetic Modifications and Clonal Evolution Ari Melnick 7:30 AM 9:00 AM Mechanisms of Sensitivity and Resistance to Epigenetic Therapies Mark Dawson Session Name: Update in Large Cell Lymphoma Session Location: Hall D (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Utilizing the Pathology Report to Inform Treatment Options Jonathan Friedberg 7:30 AM 9:00 AM Understanding the Lymphoma Pathology Report Eric Hsi 7:30 AM 9:00 AM Treatment of the Patient with Transformed Lymphoma Silvia Montoto Session Name: 503. Hematopoiesis: Epigenetic, Transcriptional and Translational Control: Epigenetic and Transcriptional Networks in Hematopoiesis and Leukemia Session Location: W314 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Cistrome Control of Hematopoietic Stem/Progenitor Cell Function Kyle Hewitt 43 9:30 AM 11:00 AM Modular Domains within a Super Enhancer Determine Drug Resistance in Leukemia Yumi Ohtani 44 9:30 AM 11:00 AM Integrated Analysis of the Human Hematopoietic Non-Coding RNA Landscape Reveals Lnc-RNA Stem Cell Signature in AML Adrian Schwarzer 45 9:30 AM 11:00 AM GFI1 Snag Domain Methylation Directs LSD1 Recruitment to Control Transcription and Cell Fate Determination in Hematopoiesis Matthew Velinder 46 9:30 AM 11:00 AM Quantitative Proteomic and Transcriptomic Analysis Reveals Post-Transcriptional Regulation of Mitochondrial Biogenesis during Erythropoiesis Jian Xu 47 9:30 AM 11:00 AM A Hyperactive Transcriptional State Marks Genome Reactivation during Mitotic Exit Gerd Blobel 48 Session Name: 631. Chronic Myeloid Leukemia: Biology and Pathophysiology, excluding Therapy: Targeting Leukemic Stem Cells in Chronic Myeloid Leukemia Session Location: W340 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM CD93 Is a Novel Biomarker of Leukemia Stem Cells in Chronic Myeloid Leukemia Ross Kinstrie 49 9:30 AM 11:00 AM Targeting of Quiescent and Proliferating CML Stem Cells By DNA Repair Inhibitors Katherine Sullivan 50 9:30 AM 11:00 AM Knockdown (KD) of Mir-126 Expression Enhances Tyrosine Kinase Inhibitor (TKI)-Mediated Targeting of Chronic Myelogenous Leukemia (CML) Stem Cells Bin Zhang 51 9:30 AM 11:00 AM A New AHI-1-DNM2-BCR-ABL Complex Regulates Leukemic Properties of Primitive CML Cells through Mediation of Cellular Endocytosis and ROS-Induced Autophagy Xiaohu Liu 52 9:30 AM 11:00 AM Role of the MSC-Derived Exosomal and Endogenous JAK2-SET/PP2A-Beta Catenin-Modulator Mir- 300 in Leukemic Stem/Progenitor Proliferation and Survival in CML Giovannino Silvestri 53 9:30 AM 11:00 AM Inhibition of CML Stem Cell Renewal By the Porcupine Inhibitor WNT974 Puneet Agarwal 54 Session Name: 634. Myeloproliferative Syndromes: Clinical: Early and Late Stage Trials in MPN Session Location: W224 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Telomerase Inhibitor Imetelstat Therapy in Refractory Anemia with Ring Sideroblasts with or without Thrombocytosis Geron Imetelstat Ayalew Tefferi 55 9:30 AM 11:00 AM PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks Promedior PRM-151 Srdan Verstovsek 56 9:30 AM 11:00 AM Dynamics of Mutations in Patients with ET Treated with Imetelstat Geron Imetelstat Elisabeth Oppliger Leibundgut 57 9:30 AM 11:00 AM Analysis of Outcomes By Patient Subgroups in Patients with Myelofibrosis Treated with Pacritinib Vs Best Available Therapy (BAT) in the Phase III Persist-1 Trial Pacritinib CTI BioPharma Alessandro Vannucchi 58 9:30 AM 11:00 AM Long-Term Efficacy and Safety in COMFORT-II, a Phase 3 Study Comparing Ruxolitinib with Best Available Therapy for the Treatment of Myelofibrosis: 5-Year Final Study Results Incyte Jakafi Claire Harrison 59 9:30 AM 11:00 AM Efficacy and Safety of Pegylated Interferon Alpha-2a in Patients with Essential Thrombocythemia and Polycythemia Vera: Results after a Median 7-Year Follow-up of a Phase 2 Study Lucia Masarova 60 Session Name: 732. Clinical Allogeneic Transplantation: Results I Session Location: W304 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Combined Donor and Recipient Non-HLA Genotypes Show Evidence of Genome Wide Association with Transplant Related Mortality (TRM) after HLA-Matched Unrelated Donor Blood and Marrow Transplantation (URD-BMT) (DISCOVeRY-BMT study) Lara Sucheston-Campbell 61 9:30 AM 11:00 AM Stem-Cell Transplantation in Adults with Philadelphia-Negative High-Risk Acute Lymphoblastic Leukemia in First Complete Remission: A Prospective Multicenter Trial Comparing Haploidentical Donors with Identical Sibling Donors Yu Wang 62 9:30 AM 11:00 AM Allogeneic Hematopoietic Stem Cell Transplantation for Secondary Acute Myeloid Leukemia- a Report from the Acute Leukemia Working Party of the EBMT Bipin Savani 63 9:30 AM 11:00 AM A Prognostic System Predictive of Outcomes in Persons Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome Brian Shaffer 64 9:30 AM 11:00 AM Alemtuzumab-Cyclosporine Versus Tacrolimus-Methotrexate-Sirolimus for Graft-Versus-Host Disease Prophylaxis in Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation from Unrelated Donors: Final Results of a Randomized Trial Lauren Curtis 65 9:30 AM 11:00 AM Feasibililty of Azacitidine As Bridge to Allogeneic Stem Cell Transplantation in Patients with Higher- Risk MDS or Low-Blast Count AML: Results of the BMT-AZA Multicenter Prospective Study Maria Teresa Voso 66 Session Name: Aging and Thrombosis Session Location: W308 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Animal Models of Aging Research Marc Hoylaerts SCI-4 9:30 AM 11:00 AM Vascular and Endothelial Biology of Aging Frank Faraci SCI-5 9:30 AM 11:00 AM Epidemiology of Thrombosis in Aging Weihong Tang SCI-6 Session Name: Checkpoint, Please? Session Location: Hall E2 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Cytotoxic T-lymphocyte-associated Protein 4 and Cancer Therapy James Allison SCI-7
  8. 8. 2015 BioMedTracker ASH Planner Saturday December 5- Oral Presentations 9:30 AM 11:00 AM Role of PD-1/PD-L1 in Acute and Chronic Graft Versus Host Disease Bruce Blazar SCI-8 9:30 AM 11:00 AM Checkpoint Blockade with Neoantigen Cancer Vaccines for Personalized Immunotherapy Catherine Wu SCI-9 Session Name: Genomics, The Next Frontier: Novel Approaches to Study Cancer and Development Session Location: Hall E1 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Engineering the Cancer Genome Tyler Jacks SCI-19 9:30 AM 11:00 AM Single Cell RNA seq for Analysis of Cell Fate Decisions H. Leighton Grimes SCI-20 9:30 AM 11:00 AM New Approaches for Mapping Epigenome Dynamics Steven Henikoff SCI-21 Session Name: Great Expectations: Hematology in Pregnancy Session Location: W307 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Hemolytic Disease of the Fetus and Newborn: Managing the Mother, Fetus, and Neonate Meghan Delaney 9:30 AM 11:00 AM Postpartum Hemorrhage: A Continuing Challenge Evelyn Lockhart 9:30 AM 11:00 AM Fertility Issues in Patients with Hematologic Malignancies Alison Loren Session Name: Immunological Ctrl-Alt-Del: Stem Cell Transplantation for Hematological Malignancies Session Location: Tangerine 1 (WF1) (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Immune Reconstitution Following Stem Cell Transplantation Marcel van den Brink 9:30 AM 11:00 AM Use of Alternative Donors for Allogeneic Stem Cell Transplantation Claudio Anasetti 9:30 AM 11:00 AM Graft-Versus-Host Disease vs. Graft-Versus-Leukemia Effect Robert Negrin Session Name: Managing Typical and Atypical Chronic Myeloid Leukemia Session Location: Valencia BC (W415BC) (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Molecular Monitoring in Chronic Myeloid Leukemia and the Prospects for Treatment-Free Remissions Michael Deininger 9:30 AM 11:00 AM Is There a Best Tyrosine Kinase Inhibitor for Chronic-Phase Chronic Myeloid Leukemia? Richard Larson 9:30 AM 11:00 AM What’s Different about Atypical Chronic Myeloid Leukemia and Chronic Neutrophilic Leukemia? Kim-Hien Dao Session Name: Mechanism of Phosphatidylserine Exposure Session Location: W312 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Flippases and Scramblases at Plasma Membranes that Regulate Phosphatidylserine Exposure Shigekazu Nagata SCI-31 9:30 AM 11:00 AM Platelet Phosphatidylserine Exposure, Survival and Blood Coagulation in Mice Lacking TMEM16F Gary Gilbert SCI-32 9:30 AM 11:00 AM Regulation of Platelet Procoagulant Activity Johan Heemskerk SCI-33 Session Name: Myelodysplastic Syndromes: Evolving Diagnosis and Therapy Session Location: Valencia D (W415D) (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM The Shadowlands of Myelodysplastic Syndromes: Idiopathic Cytopenias of Undetermined Significance and Clonal Hematopoiesis of Indeterminate Potential Luca Malcovati 9:30 AM 11:00 AM Reclassifying Myelodysplastic Syndromes: What's Where in the New WHO and Why Daniel Arber 9:30 AM 11:00 AM Nine Years Without a New FDA Approved Therapy for Myelodysplastic Syndromes: How Can We Break Through the Impasse? Amy DeZern Session Name: New Insights in Hemolytic Anemia Session Location: W331 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Complement in Hemolytic Anemia Robert Brodsky 9:30 AM 11:00 AM Management of Hemolytic Anemia Following Allogeneic Stem Cell Transplantation Andreas Holbro 9:30 AM 11:00 AM Diagnosis and Management of Rare Congenital Non-Immune Hemolytic Disease Patrick Gallagher Session Name: Novel Approaches to Acute Lymphoblastic Leukemia Session Location: Tangerine 3 (WF3-4) (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Management Of Adult BCR/ABL1+ Acute Lymphocytic Leukemia Robin Foà 9:30 AM 11:00 AM Novel Monoclonal Antibodies in Acute Lymphocytic Leukemia Daniel DeAngelo 9:30 AM 11:00 AM How Can We Improve on the Already Impressive Results in Pediatric Acute Lymphocytic Leukemia? Angela Thomas Session Name: Optimizing Therapy in Sickle Cell Disease Session Location: Chapin Theater (W320) (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Optimizing Hydroxyurea Therapy in Sickle Cell Disease Russell Ware 9:30 AM 11:00 AM The Five Key Things You Need to Know to Manage Adult Patients with Sickle Cell Disease Sophie Lanzkron 9:30 AM 11:00 AM Can Selectin and Invariant Natural Killer T-Cell Therapies Meet the Needs of People with Sickle Cell Disease? Joshua Field Session Name: Pediatric Hematological Malignancies: Beyond Acute Lymphocytic Leukemia Session Location: Valencia A (W415A) (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Hodgkin Lymphoma in Children and Adolescents Kara Kelly 9:30 AM 11:00 AM Acute Myeloid Leukemia in Children and Adolescents E. Kolb 9:30 AM 11:00 AM Non-Hodgkin Lymphoma in Children and Adolescents Rachel Kobos
  9. 9. 2015 BioMedTracker ASH Planner Saturday December 5- Oral Presentations Session Name: Practical Management of T-Cell and Natural Killer Cell Lymphomas Session Location: Hall D (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Peripheral T-Cell Lymphoma Not Otherwise Specified and Anaplastic Large Cell Lymphoma Anne Beaven 9:30 AM 11:00 AM Choosing a Systemic Therapy for Advanced Mycosis Fungoides and Sezary Syndrome Madeleine Duvic 9:30 AM 11:00 AM Zebras and Hen's Teeth: Recognition and Management of Rare T and NK Lymphomas Steven Horwitz Session Name: Recent Insights into Efficacy of Red Blood Cells in Transfusions and Physiology Session Location: W414AB (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM New Insights in the Potential Effect of Transfusing Red Blood Cells that Have Been Stored for Different Periods Simone Glynn SCI-37 9:30 AM 11:00 AM Impact of Genetic Predispositions, Diet, and Environment on Storage of Red Blood Cells Steven Spitalnik SCI-38 9:30 AM 11:00 AM Role of Red Cells in Thrombosis and Hemostasis John Weisel SCI-39 Session Name: Special Education Session on Clinical Applications of Newly Approved Drugs Session Location: Tangerine 2 (WF2) (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Blinatumomab Amgen Blincyto Anjali Advani 9:30 AM 11:00 AM Idarucizumab Boehringer Ingelheim Praxbind Kenneth Bauer 9:30 AM 11:00 AM Panobinostat Novartis Farydak Sagar Lonial Session Name: Telomeres and Bone Marrow Failure Session Location: W315 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Mechanisms Governing Disruption of Telomere Maintenance in Dyskeratosis Congenita Steven Artandi SCI-49 9:30 AM 11:00 AM Therapeutic Strategies for the Treatment of Telomere-Associated Diseases Maria Blasco SCI-50 9:30 AM 11:00 AM Extrahematopoietic Manifestations of Telomere Syndromes Mary Armanios SCI-51 Session Name: The Path Toward Curing Multiple Myeloma Session Location: W311 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Characterization of Minimal Residual Disease Alberto Orfao SCI-52 9:30 AM 11:00 AM Clonal Heterogeneity and Genetic Instability of Multiple Myeloma and Impact on Treatment Jonathan Keats SCI-53 9:30 AM 11:00 AM Mathematical Models of Cancer Evolution and Cure Kenneth Shain Session Name: Career Development Lunch- Room 1 Session Location: Regency Ballroom P (Hyatt Regency Orlando) Session Time: 11:15 AM-12:15 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 11:15 AM 12:15 PM Laboratory & Translational Hematology Careers Ross Levine 11:15 AM 12:15 PM Industry Careers Benjamin Kim 11:15 AM 12:15 PM Industry Careers William Hobbs 11:15 AM 12:15 PM Government Careers Ann Farrell 11:15 AM 12:15 PM Government Careers Wyndham Wilson 11:15 AM 12:15 PM Pediatric Hematology/Oncology Careers Mitchell Weiss 11:15 AM 12:15 PM Pediatric Hematology/Oncology Careers William Carroll 11:15 AM 12:15 PM PhD Careers Ellinor Peerschke 11:15 AM 12:15 PM PhD Careers Margaret Goodell 11:15 AM 12:15 PM Clinical Careers in Hematology Alexander Spira 11:15 AM 12:15 PM Medical Educators in Hematology Jason Gotlib 11:15 AM 12:15 PM Medical Educators in Hematology Jennifer Kesselheim 11:15 AM 12:15 PM Transfusion Medicine Careers Gary Schiller 11:15 AM 12:15 PM Laboratory & Translational Hematology Careers Pavan Reddy 11:15 AM 12:15 PM Transfusion Medicine Careers Marc Zumberg 11:15 AM 12:15 PM Clinical Benign Hematology Careers Margaret Ragni 11:15 AM 12:15 PM Clinical Careers in Hematology Robb Friedman 11:15 AM 12:15 PM Clinical Malignant Hem/BMT Careers Richard Stone 11:15 AM 12:15 PM Clinical Benign Hematology Careers Kenneth Bauer 11:15 AM 12:15 PM Clinical Malignant Hem/BMT Careers David Avigan Session Name: Career Development Lunch- Room 2 Session Location: Regency Ballroom Q (Hyatt Regency Orlando) Session Time: 11:15 AM-12:15 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 11:15 AM 12:15 PM Clinical Malignant Hem/BMT Careers Steven Devine 11:15 AM 12:15 PM Clinical Malignant Hem/BMT Careers John DiPersio 11:15 AM 12:15 PM Clinical Benign Hematology Careers Kenneth Ataga 11:15 AM 12:15 PM Clinical Benign Hematology Careers Gowthami Arepally 11:15 AM 12:15 PM Laboratory & Translational Hematology Careers Robert Flaumenhaft 11:15 AM 12:15 PM Industry Careers Solveig Ericson 11:15 AM 12:15 PM Industry Careers Jeffery Kutok 11:15 AM 12:15 PM Government Careers Nicole Gormley 11:15 AM 12:15 PM Government Careers Louis Staudt 11:15 AM 12:15 PM Pediatric Hematology/Oncology Careers Smita Bhatia 11:15 AM 12:15 PM Pediatric Hematology/Oncology Careers Staci Arnold 11:15 AM 12:15 PM PhD Careers Emmanuelle Passegue 11:15 AM 12:15 PM PhD Careers John Crispino 11:15 AM 12:15 PM Medical Educators in Hematology Leslie Kersun 11:15 AM 12:15 PM Medical Educators in Hematology Alexandra Wolanskyj
  10. 10. 2015 BioMedTracker ASH Planner Saturday December 5- Oral Presentations 11:15 AM 12:15 PM Clinical Careers in Hematology Michael Lankiewicz 11:15 AM 12:15 PM Transfusion Medicine Careers Lawrence Goodnough 11:15 AM 12:15 PM PhD Careers Barbara Furie 11:15 AM 12:15 PM Laboratory & Translational Hematology Careers Catherine Bollard Session Name: Continuing Conversations with the Speakers on Checkpoint Please? Session Location: W232A (Orange County Convention Center) Session Time: 11:15 AM-12:15 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 11:15 AM 12:15 PM Speaker Bruce Blazar 11:15 AM 12:15 PM Speaker James Allison 11:15 AM 12:15 PM Speaker Catherine Wu Session Name: Continuing Conversations with the Speakers on Genomics, the Next Frontier: Novel Approaches to Study Cancer and Development Session Location: W231C (Orange County Convention Center) Session Time: 11:15 AM-12:15 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 11:15 AM 12:15 PM Speaker H. Leighton Grimes 11:15 AM 12:15 PM Speaker Tyler Jacks 11:15 AM 12:15 PM Speaker Steven Henikoff Session Name: 114. Hemoglobinopathies, Excluding Thalassemia – Clinical: Novel Insights into Pathophysiology in Sickle Cell Disease Session Location: W340 (Orange County Convention Center) Session Time: 12:00 PM-1:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 12:00 PM 1:30 PM Thermal Pain and Pain Anticipation Induce a Decrease in Microvascular Perfusion in Sickle Cell and Normal Subjects Maha Khaleel 67 12:00 PM 1:30 PM Ischemic Stroke in Children and Young Adults with Sickle Cell Disease (SCD) in the Post-STOP Era Janet Kwiatkowski 68 12:00 PM 1:30 PM Elevations in MR Measurements of Whole Brain and Regional Cerebral Blood Flow and Oxygen Extraction Fraction Suggest Cerebral Metabolic Stress in Children with Sickle Cell Disease Unaffected By Overt Stroke Melanie Fields 69 12:00 PM 1:30 PM Association of Hemoglobin S and C Traits with Kidney Disease in African Americans in the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study Rakhi Naik 70 12:00 PM 1:30 PM Survival in Sickle Cell Disease: Data from a Well-Resourced, National Health System Setting Kate Gardner 71 12:00 PM 1:30 PM Association Between Hyperhemolysis and Vascular Complications in Sickle Cell Disease Sub- Saharan African Patients Brigitte Ranque 72 Session Name: 311. Disorders of Platelet Number or Function: Genetics of Inherited and Acquired Thrombocytopenias Session Location: W315 (Orange County Convention Center) Session Time: 12:00 PM-1:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 12:00 PM 1:30 PM Genes Influencing the Development and Severity of Chronic ITP Identified through Whole Exome Sequencing Jenny Despotovic 73 12:00 PM 1:30 PM Blvrb Mutation Induces Thrombocytosis Via Redox Dysregulation in the Heme Degradation Pathway Song Wu 74 12:00 PM 1:30 PM Functional Characterization of a Novel GFI1B Mutation Causing Congenital Macrothrombocytopenia Katsumasa Kitamura 75 12:00 PM 1:30 PM A Dominant Negative Mutation (p.P214L) in ETV6 is Associated with Megakaryocyte and Erythroid Transcript Misregulation Leila Noetzli 76 12:00 PM 1:30 PM New CNV Regions Identified in ITP Provide Evidence for Genetic Predisposition M. Cem Ar 77 12:00 PM 1:30 PM Homozygous Mutation of the ETS DNA-Binding Domain of FLI1 Causes a Bleeding Disorder with Giant Alpha Granules Similar to Paris-Trousseau Thrombocytopenia William Stevenson 78 Session Name: 612. Acute Lymphoblastic Leukemia: Clinical Studies I Session Location: W230 (Orange County Convention Center) Session Time: 12:00 PM-1:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 12:00 PM 1:30 PM Effectiveness of High-Dose MTX Therapy for Adult Ph-Negative ALL By Randomized Trial: JALSG ALL202-O Toru Sakura 79 12:00 PM 1:30 PM A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial Daniel DeAngelo 80 12:00 PM 1:30 PM Multicenter Total Therapy Gimema LAL 1509 Protocol for De Novo Adult Ph+ Acute Lymphoblastic Leukemia (ALL) Patients. Updated Results and Refined Genetic-Based Prognostic Stratification Sabina Chiaretti 81 12:00 PM 1:30 PM 6-Mercaptopurine (6MP) Intake during Maintenance for Childhood Acute Lymphoblastic Leukemia (ALL) - a Comparison of Self-Report and Electronic Monitoring: A Report from the Children's Oncology Group (COG) Study AALL03N1 Wendy Landier 82 12:00 PM 1:30 PM Frontline Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper- CVD) for Older Patients with Acute Lymphoblastic Leukemia (ALL) Elias Jabbour 83 12:00 PM 1:30 PM Characterization of Leukemias with ETV6-ABL1 Fusion Marketa Zaliova 84 Session Name: 617. Acute Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Omics-based Approaches for the Identification of Novel Genetic Modalities in AML Session Location: Tangerine 3 (WF3-4) (Orange County Convention Center) Session Time: 12:00 PM-1:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 12:00 PM 1:30 PM Personally Tailored Risk Prediction of AML Based on Comprehensive Genomic and Clinical Data Moritz Gerstung 85
  11. 11. 2015 BioMedTracker ASH Planner Saturday December 5- Oral Presentations 12:00 PM 1:30 PM The Complexity of Interpreting Genomic Data in Patients with Primary and Secondary Acute Myeloid Leukemia (AML) Aziz Nazha 86 12:00 PM 1:30 PM Discovery and Functional Validation of Novel Pediatric Specific FLT3 Activating Mutations in Acute Myeloid Leukemia: Results from the COG/NCI Target Initiative Katherine Tarlock 87 12:00 PM 1:30 PM Genomic and Proteomic Analysis of Primary Chemoresistance and Induction Failure in Acute Myeloid Leukemia Fiona Brown 88 12:00 PM 1:30 PM Dysregulation of DNA Methylation Involves in Progression of Myeloid Leukemia in Down Syndrome Satoshi Saida 89 12:00 PM 1:30 PM Immunophenotypic-Defined Stage of Leukemia Differentiation Arrest Identifies Oncogenic and Metabolic Signatures in AML Francois Vergez 90 Session Name: 637. Myelodysplastic Syndromes – Clinical Studies: New Therapeutic Approaches Session Location: W331 (Orange County Convention Center) Session Time: 12:00 PM-1:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 12:00 PM 1:30 PM Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial Novartis Promacta Esther Oliva 91 12:00 PM 1:30 PM Luspatercept Treatment Leads to Long Term Increases in Hemoglobin and Reductions in Transfusion Burden in Patients with Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS): Preliminary Results from the Phase 2 PACE-MDS Extension Study Acceleron Pharma Luspatercept Aristoteles Giagounidis 92 12:00 PM 1:30 PM A Phase 1b Study of Birinapant in Combination with 5-Azacitadine in Patients with Myelodysplastic Syndrome Who Are Naïve, Refractory or Have Relapsed to 5-Azacitadine TetraLogic Birinapant Gautam Borthakur 93 12:00 PM 1:30 PM Low-Dose Hypomethylating Agents (HMAs) Are Effective in Patients (Pts) with Low- or Intermediate-1-Risk Myelodysplastic Syndrome (MDS): A Report on Behalf of the MDS Clinical Research Consortium Nicholas Short 94 12:00 PM 1:30 PM Outcome of Patients Treated for Myelodysplastic Syndromes after Failure of Lenalidomide Therapy Thomas Prebet 95 12:00 PM 1:30 PM Predicting MDS Response to Drug Therapies Based on a New Method of Interpreting the MDS Mutanome Cindy Medina 96 Session Name: 703. Adoptive Immunotherapy: Clinical Studies Session Location: W314 (Orange County Convention Center) Session Time: 12:00 PM-1:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 12:00 PM 1:30 PM Adoptive Transfer of WT1-Specific TCR Gene-Transduced Lymphocytes in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia Isao Tawara 97 12:00 PM 1:30 PM Wilms´Tumor 1 Protein Is Highly Expressed on Malignant Plasma Cells and Provides a Novel Target for Immunotherapeutic Approaches Guenther Koehne 98 12:00 PM 1:30 PM Allogeneic T-Cells Expressing an Anti-CD19 Chimeric Antigen Receptor Cause Remissions of B-Cell Malignancies after Allogeneic Hematopoietic Stem Cell Transplantation without Causing Graft- Versus-Host Disease James Kochenderfer 99 12:00 PM 1:30 PM CD4 CAR T Cells Mediate CD8-like Cytotoxic Anti-Leukemic Effects Resulting in Leukemic Clearance and Are Less Susceptible to Attenuation By Endogenous TCR Activation Than CD8 CAR T Cells Yinmeng Yang 100 12:00 PM 1:30 PM Human Cytokine-Induced Memory-like NK Cells Exhibit in Vivo Anti-Leukemia Activity in Xenografted NSG Mice and in Patients with Acute Myeloid Leukemia (AML) Rizwan Romee 101 12:00 PM 1:30 PM Phase I Trial of IL-21 Ex Vivo Expanded NK Cells Administration to Prevent Disease Relapse after Haploidentical Stem-Cell Transplantation for Myeloid Leukemias Stefan Ciurea 102 Session Name: Ham-Wasserman Lecture Session Location: Hall D (Orange County Convention Center) Session Time: 12:30 PM-1:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 12:30 PM 1:30 PM Game of Clones: The Genomic Evolution of Severe Congenital Neutropenia Ivo Touw Session Name: 311. Disorders of Platelet Number or Function: Thrombotic Microangiopathies Session Location: W315 (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM Modified Ham Test Distinguishes aHUS from TTP and Predicts Response to Eculizumab Eleni Gavriilaki 103 2:00 PM 3:30 PM Anti-Idiotypic-Designed-Ankyrin-Repeat-Molecules (DARPins) Universally Neutralize Plasma- Derived Autoantibodies in Acquired TTP Patients Monica Schaller 104 2:00 PM 3:30 PM Human Neutrophil Peptides (HNPs) Enhance Thrombus Formation Under Flow By Inhibiting Proteolytic Activity of Plasma ADAMTS13 Metalloprotease Vikram Pillai 105 2:00 PM 3:30 PM Identification of T Cell Epitope of ADAMTS13 in Thrombotic Thrombocytopenic Purpura Patients Laurent Gilardin 106 2:00 PM 3:30 PM ADAMTS13 Reactive CD4+ T Cells Targeting CUB-2 Domain Derived Peptides in Autoimmune Thrombotic Thrombocytopenic Purpura Fabian Verbij 107 2:00 PM 3:30 PM Profiling the Autoantibody Repertoire of Acquired Thrombotic Thrombocytopenic Purpura (aTTP) Patients By Single Cell Sorting and Deep Sequencing of Splenic B-Cells Magdalena Skowronska 108 Session Name: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Refining The Molecular Roadmap In NHL Session Location: W312 (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM Comprehensive MYC and BCL2 Genetic Profiling in De Novo Diffuse Large B-Cell Lymphoma Demonstrates Clinically Relevant Genetic Alterations According to Cell of Origin Subtype Daisuke Ennishi 109 2:00 PM 3:30 PM Discovery of Recurrent Mutations Associated with Chemo-Immunotherapy Relapse in Diffuse Large B-Cell Lymphoma Jillian Wise 110 2:00 PM 3:30 PM Genetic Alterations of Gα13 Signaling Pathway with BCL2 over-Expression Confers Lymphoma Dissemination and Inferior Outcome in Germinal Center B Cell Diffuse Large B Cell Lymphoma Daisuke Ennishi 111 2:00 PM 3:30 PM Analysis of 54 Follicular Lymphomas By Whole Exome Sequencing Identifies Multiple Novel Recurrently Mutated Pathways Sami Malek 112 2:00 PM 3:30 PM Frequent Activating Somatic Alterations in T-Cell Receptor / NF-κb Signaling in Adult T-Cell Leukemia/Lymphoma Keisuke Kataoka 113 2:00 PM 3:30 PM Noninvasive Genotyping and Assessment of Treatment Response in Diffuse Large B Cell Lymphoma Florian Scherer 114 Session Name: 652. Myeloma: Pathophysiology and Pre-Clinical Studies, excluding Therapy: Novel Immunotherapeutics and the Impact of the Microenvironment Session Location: W414AB (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM CAR-Engineered T Cells Specific for the Elotuzumab Target SLAMF7 Eliminate Primary Myeloma Cells and Confer Selective Fratricide of SLAMF7+ Normal Lymphocyte Subsets Sophia Danhof 115
  12. 12. 2015 BioMedTracker ASH Planner Saturday December 5- Oral Presentations 2:00 PM 3:30 PM Bypassing the Constraint for Chimeric Antigen Receptor (CAR) Development in T-Cells Expressing the Targeted Antigen: Improvement of Anti-CS1 CAR Activity in Allogenic TCRa/CS1 Double Knockout T-Cells for the Treatment of Multiple Myeloma (MM) UCARTCS1 Cellectis Roman Galetto 116 2:00 PM 3:30 PM Target Expression, Preclinical Activity and Mechanism of Action of EM801: A Novel First-in-Class Bcma T-Cell Bispecific Antibody for the Treatment of Multiple Myeloma Anja Seckinger 117 2:00 PM 3:30 PM A Novel Bispecific CD38 Antibody Eradicates Multiple Myeloma in a Mouse Model Following Yttrium-90-DOTA Capture Damian Green 118 2:00 PM 3:30 PM Anti-Sclerostin Treatment Prevents Multiple Myeloma Induced Bone Loss and Reduces Tumor Burden Michaela Reagan 119 2:00 PM 3:30 PM Niche-Dependent Growth of Malignant and Pre-Neoplastic Plasma Cells in Humanized Mice Rituparna Das 120 Session Name: Contemporary Therapy of Lymphoma Session Location: Chapin Theater (W320) (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM What Is the Role of Autologous Transplant for Lymphoma in the Current Era? Patrick Stiff 2:00 PM 3:30 PM Checkpoint Blockade in Lymphoma Philippe Armand 2:00 PM 3:30 PM B Cell Receptor Pathway Modulators in Non-Hodgkin Lymphoma Kristie Blum Session Name: Cytosis: Too Much of a Good Thing Session Location: W224 (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM Diagnosis and Management of Mastocytosis: An Emerging Challenge in Applied Hematology Peter Valent 2:00 PM 3:30 PM Eosinophilia: A Pragmatic Approach to Diagnosis and Treatment Amy Klion 2:00 PM 3:30 PM Lymphocytosis, Lymphadenopathy: Benign or Malignant? Jane Winter Session Name: Genome Therapies for Hemoglobinopathies Session Location: Hall D (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM DNA Editing: A Primer Prashant Mali SCI-16 2:00 PM 3:30 PM Modified IPS Cells for Hemoglobinopathies Tim Townes SCI-17 2:00 PM 3:30 PM Bench to Bedside-Gene Therapy for Thalassemia and Sickle Cell Disease Philippe Leboulch SCI-18 Session Name: Hematopoiesis and the Niche Session Location: W314 (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM Vascular Niche-Derived Angiocrine Factors Specify and Maintain Hematopoietic Stem Cells Shahin Rafii SCI-25 2:00 PM 3:30 PM Noncellular Niche Influences: Nervous System Mediators, Metabolic Mediators, and Hypoxia/Oxidative Stress Simón Méndez-Ferrer SCI-26 2:00 PM 3:30 PM Heterogeneity in the Making of Blood David Scadden SCI-27 Session Name: Inflammatory Signaling: Tailoring Myelopoiesis in Health and Disease Session Location: Valencia BC (W415BC) (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM Educating the Innate Immune System Scott Worthen SCI-28 2:00 PM 3:30 PM The Role of Receptor Interacting Protein Kinase in Myelopoiesis in Health and Disease John Silke SCI-29 2:00 PM 3:30 PM Reacting to Inflammatory Signals Nadia Carlesso SCI-30 Session Name: Junior-Faculty Development Education Session: Understanding the Basics of the Academic Job Session Location: W109 (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM Strategies for Success for Junior Faculty Stephanie Lee 2:00 PM 3:30 PM Understanding Promotion and Tenure Robert Liem 2:00 PM 3:30 PM Looking for an Academic Job Janis Abkowitz 2:00 PM 3:30 PM Understanding Promotion and Tenure John Wagner Session Name: Precision Medicine in Cancer Therapy: N-of-1 Session Location: Hall E1 (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM Insights from the Study of Exceptional Responders Nikhil Wagle 2:00 PM 3:30 PM Precision Therapy of Lymphoma Inspired by Functional and Structural Genomics Louis Staudt 2:00 PM 3:30 PM Functional Screening to Guide Personalized Cancer Therapy Jeffrey Tyner
  13. 13. 2015 BioMedTracker ASH Planner Saturday December 5- Oral Presentations Session Name: Recent Advances in Histiocytic Neoplasms Session Location: W230 (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM Treatment of Langerhans Cell Histiocytosis: Role of BRAF/MAPK Inhibition Sheila Weitzman 2:00 PM 3:30 PM Biological and Clinical Significance of Somatic Mutations in Langerhans Cell Histiocytosis and Related Histiocytic Neoplastic Disorders Donald Parsons 2:00 PM 3:30 PM Uncommon Histiocyte Disorders: Rosai-Dorfman Disease, Juvenile Xanthogranuloma, and Erdheim- Chester Disease Julien Haroche Session Name: Send in the Clones: Stem Cell Succession, Replicative Stress and Somatic Reversion Session Location: Tangerine 1 (WF1) (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM In vivo Stem Cell Clonal Dynamics Fernando Camargo SCI-40 2:00 PM 3:30 PM Stem Cell Replicative Stress and Clonal Exhaustion Michael Milsom SCI-41 2:00 PM 3:30 PM Clonal Reversion in Genetic Syndromes: Gene Therapy at Its Best Marjolijn Jongmans SCI-42 Session Name: Special Symposium on Quality Session Location: W304 (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM Quality Measures in Practice: The Medicare Access and CHIP Reauthorization Act of 2015 (MACRA)—What Clinicians Need to Know Lemeneh Tefera 2:00 PM 3:30 PM Quality Measures, Quality Reporting, and Value-Based Remuneration: How Did We Get Here and Where Are We Going? Helen Burstin 2:00 PM 3:30 PM Pay-for-Performance: Reviewing the Evidence Andrew Ryan Session Name: Targeting the Tumor Microenvironment in Lymphoid Malignancies Session Location: Valencia D (W415D) (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM The Role of the Tumor Microenvironment in Lymphoid Malignancies Christian Steidl SCI-46 2:00 PM 3:30 PM Targeting the Immune Checkpoint Network in Lymphoid Malignancy Alan Ramsay SCI-47 2:00 PM 3:30 PM Re-educating the Tumor Microenvironment in the Clinic Stephen Ansell SCI-48 Session Name: Treatment of Acute Myeloid Leukemia: Moving Beyond 3 + 7 Session Location: Hall E2 (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM Antigen-Specific Immunotherapies for Acute Myeloid Leukemia Roland Walter 2:00 PM 3:30 PM Molecularly Targeted Therapies for Acute Myeloid Leukemia Eytan Stein 2:00 PM 3:30 PM Newer Approaches to Transplantation in Acute Myeloid Leukemia Marcos de Lima Session Name: Update on Diagnosis and Management of Thrombotic Thrombocytopenic Purpura Session Location: Tangerine 3 (WF3-4) (Orange County Convention Center) Session Time: 2:00 PM-3:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 2:00 PM 3:30 PM Beyond Simple Plasma Exchange: New Approaches in Treatment of Thrombotic Thrombocytopenic Purpura Paul Coppo 2:00 PM 3:30 PM What’s New in the Diagnosis and Pathophysiology of Thrombotic Thrombocytopenic Purpura J. Evan Sadler 2:00 PM 3:30 PM Syndromes of Thrombotic Microangiopathy Associated with Pregnancy James George Session Name: 321. Blood Coagulation and Fibrinolytic Factors: Biochemistry and Engineering of Coagulation Proteins Session Location: W315 (Orange County Convention Center) Session Time: 4:00 PM-5:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 4:00 PM 5:30 PM The X-Ray Structure of a Variant of Human Factor V Provides Structural Insights into the Procofactor Activation Paradox Shekhar Kumar 121 4:00 PM 5:30 PM Long-Range Allosteric Linkage Between Exosites Reciprocally Regulates the Zymogenicity of Prothrombin Derivatives Joseph Micucci 122 4:00 PM 5:30 PM Bioengineering Coagulation Factor VIII through Ancestral Protein Reconstruction Philip Zakas 123 4:00 PM 5:30 PM Prothrombin Membrane Binding and Gla-Dependent Function Are Not Required for Effective Hemostasis In Vivo Lindsey Greene 124 4:00 PM 5:30 PM Tissue Factor Decryption By Oxidative Stress-Induced Lipid Peroxidation: Potential Mechanisms Shabbir Ansari 125 4:00 PM 5:30 PM Engineered Factor Xa Variants Retain Procoagulant Activity Independent of Direct Factor Xa- Inhibitors Daniël Verhoef 126
  14. 14. 2015 BioMedTracker ASH Planner Saturday December 5- Oral Presentations Session Name: 622. Non-Hodgkin Lymphoma: Biology, excluding Therapy: Clinical Implications of Genomic Studies of B-cell Lymphomas Session Location: W312 (Orange County Convention Center) Session Time: 4:00 PM-5:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 4:00 PM 5:30 PM Liquid Biopsy As a Tool for Monitoring the Genotype of Diffuse Large B-Cell Lymphoma Silvia Rasi 127 4:00 PM 5:30 PM Next Generation Sequencing Identifies a Distinct Transcriptional Profile, Including Isoform Dysregulation That Segue with Genomic Alterations in Waldenstrom's Macoglobulinemia Zachary Hunter 128 4:00 PM 5:30 PM Recurrent Mutations of the Exportin 1 Gene (XPO1) in Primary Mediastinal B-Cell Lymphoma: A Lysa Study Fabrice Jardin 129 4:00 PM 5:30 PM Dynamic Noninvasive Genomic Monitoring for Outcome Prediction in Diffuse Large B-Cell Lymphoma David Kurtz 130 4:00 PM 5:30 PM Study of the Subclonal Mutations in Primary Diffuse Large B-Cell Lymphoma Yan Asmann 131 4:00 PM 5:30 PM Characterization of MYD88 mutated Lymphoplasmacytic Lymphoma in Comparison to MYD88 mutated Chronic Lymphocytic Leukemia Constance Baer 132 Session Name: 632. Chronic Myeloid Leukemia: Therapy: Clinical Trials, Observations, and Molecular Monitoring Session Location: Valencia BC (W415BC) (Orange County Convention Center) Session Time: 4:00 PM-5:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 4:00 PM 5:30 PM Personalized Daily Doses of Imatinib By Therapeutic Drug Monitoring Increase the Rates of Molecular Responses in Patients with Chronic Myeloid Leukemia. Final Results of the Randomized OPTIM Imatinib Study Philippe Rousselot 133 4:00 PM 5:30 PM Combination of Dasatinib and Peg-Interferon Alpha 2b in Chronic Phase Chronic Myeloid Leukemia (CP-CML) First Line: Preliminary Results of a Phase II Trial, from the French Intergroup of CML (Fi- LMC) Lydia ROY 134 4:00 PM 5:30 PM Quantification of BCR-ABL with Digital PCR Results in a Significantly Lower Rate of Deep Molecular Responses When Compared to RT-qPCR in CML Patients Treated in the ENEST1st Trial Georg-Nikolaus Franke 135 4:00 PM 5:30 PM International Scale (IS)-Standardized BCR-ABL1 Digital Polymerase Chain Reaction (dPCR) Assays Using ABL1, BCR, and GUS Control Genes for Measuring Deep Molecular Response (MR) in Chronic Myeloid Leukemia (CML) Alice Huang 136 4:00 PM 5:30 PM Osteoarticular Pain after Discontinuation of Tyrosine Kinase Inhibitors (TKI): A French Cohort Marc Berger 137 4:00 PM 5:30 PM ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy Novartis ABL-001 Oliver Ottmann 138 Session Name: 636. Myelodysplastic Syndromes – Basic and Translational Studies: Consequences of Splicing Factor Alterations and Genetic Instability Session Location: Valencia D (W415D) (Orange County Convention Center) Session Time: 4:00 PM-5:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 4:00 PM 5:30 PM Different Mutant Splicing Factors Cause Distinct Missplicing Events and Give Rise to Different Clinical Phenotypes in Myelodysplastic Syndromes Yusuke Shiozawa 139 4:00 PM 5:30 PM Sf3b1 K700E Mutation Impairs Pre-mRNA Splicing and Definitive Hematopoiesis in a Conditional Knock-in Mouse Model Annalisa Mupo 140 4:00 PM 5:30 PM Integrative Genome-Wide Analysis of RNA Binding and Splicing Reveals Complex Loss and Gain of Function Alterations By SRSF2 P95 Mutations in Myelodysplasia Kai Rejeski 141 4:00 PM 5:30 PM Lineage-Specific Aberrant mRNA Splicing By U2AF1 Mutation Alters Erythroid and Granulomonocytic Differentiation Bon Ham Yip 142 4:00 PM 5:30 PM Ubiquitin Editing of a Spliceosome Auxiliary Factor By TRAF6 Links Chronic TLR Signaling with Hematopoietic Defects and Myelodysplasia Jing Fang 143 4:00 PM 5:30 PM Inflammaging-Associated Metabolic Alterations Foster Development of the MDS Genotype Erika Eksioglu 144 Session Name: 702. Experimental Transplantation: Immune Function, GVHD, and Graft-versus-Tumor Effects: Novel Approaches to Dampen GVHD Session Location: W414AB (Orange County Convention Center) Session Time: 4:00 PM-5:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 4:00 PM 5:30 PM Targeting the Human Notch 2-BCR Axis: A Driver of B-Cell Hyper-Responsiveness in Active Chronic Graft-Versus Host Disease (cGVHD) Jonathan Poe 145 4:00 PM 5:30 PM Recipient Dendritic Cells Are Regulated By MiR-146a during Acute GvHD Kathrin Hanke 146 4:00 PM 5:30 PM Loss of Programmed Death Ligand-1 Expression on Donor T Cells Lessens Acute Graft-Versus-Host Disease Lethality Asim Saha 147 4:00 PM 5:30 PM NLRP6 in Host Target Tissues Exacerbates Graft-Versus-Host Disease Tomomi Toubai 148 4:00 PM 5:30 PM ATG5 Dependent Autophagy Uncouples T Cell Functions and Modulates Experimental Graft-Versus- Host Disease Katherine Oravecz-Wilson 149 4:00 PM 5:30 PM Blockade of Interleukin 27 Signaling Attenuates Graft Versus Host Disease By Augmenting CD4+ and CD8+ Regulatory T Cell Reconstitution Ludovic Belle 150 Session Name: 732. Clinical Allogeneic Transplantation: Results II Session Location: W304 (Orange County Convention Center) Session Time: 4:00 PM-5:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 4:00 PM 5:30 PM Related Nonmyeloablative Haploidentical (mini-haplo) Blood or Marrow Transplantation (BMT) with High-Dose Post-Transplant Cyclophosphmade (PTCy) for Acute Myeloid Leukemia (AML): Donor Age Impacts Outcome Margaret Showel 151 4:00 PM 5:30 PM Results of a Two-Arm Phase II Clinical Trial Using Post-Transplantation Cyclophosphamide for Prevention of Graft-Versus-Host Disease in Haploidentical and Mismatched Unrelated Donors Hematopoietic Stem-Cell Transplantation Sameh Gaballa 152 4:00 PM 5:30 PM Outcomes of Cord Blood Transplantation from an HLA-Identical Sibling for Patients with Inherited or Acquired Bone Marrow Failure Disorders: A Report from Eurocord, Cord Blood Committee (CBC- CTIWP) and Severe Aplastic Anemia Working Party (SAAWP) of the European Group of Blood and Bone Marrow Transplantation (EBMT) Simona Pagliuca 153 4:00 PM 5:30 PM The Impact of Donor Age on Outcome after Unrelated Bone Marrow Transplantation: Comparison with Unrelated Cord Blood Transplantation Sachiko Seo 154 4:00 PM 5:30 PM Reduced-Intensity Versus Myeloablative Conditioning for Unrelated Cord Blood Transplantation in Adults with Acute Leukemia: A Report from Eurocord, the Acute Leukemia Working Party and the Cord Blood Committee of the Cellular Therapy & Immunobiology Working Party of the European Group for Blood and Marrow Transplantation Frederic Baron 155 4:00 PM 5:30 PM HLA-Mismatched Microtransplantation Vs HLA-Matched Nonmyeloablative Transplantation for Acute Myeloid Leukemia in Intermediate-Risk: Comparable Survival but Avoids of Gvhd Huisheng Ai 156 Session Name: ASH/ASCP Summit on Myelodysplastic Syndromes Session Location: W230 (Orange County Convention Center) Session Time: 4:00 PM-5:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 4:00 PM 5:30 PM Treating MDS Outliers: Patients with Secondary Diseases and Comorbidities Rami Komrokji 4:00 PM 5:30 PM Prognostic Systems Masquerading As Default Staging Systems for Myelodysplastic Syndromes Mikkael Sekeres 4:00 PM 5:30 PM MDS Mimics: What You See Is Not Always What You Get Timothy Miley
  15. 15. 2015 BioMedTracker ASH Planner Saturday December 5- Oral Presentations Session Name: Evolving Issues in Anticoagulation Session Location: Tangerine 1 (WF1) (Orange County Convention Center) Session Time: 4:00 PM-5:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 4:00 PM 5:30 PM Anticoagulation in Children and Adolescents Guy Young 4:00 PM 5:30 PM Monitoring and Reversal of Direct Oral Anticoagulants Adam Cuker 4:00 PM 5:30 PM Using Direct Oral Anticoagulants in Cancer and Other High-Risk Populations Harry Büller Session Name: Genomically Engineered Stem Cells: A Brave New World for Therapeutics Session Location: Hall E1 (Orange County Convention Center) Session Time: 4:00 PM-5:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 4:00 PM 5:30 PM Making Hematopoietic Stem Cells: Backwards and Sideways Derrick Rossi 4:00 PM 5:30 PM Blood Cells from Pluripotent Stem Cells: The Platelet Story Mortimer Poncz 4:00 PM 5:30 PM Engineering Universal Donor Stem Cells David Russell Session Name: Multiple Advances in Myeloma Session Location: Hall D (Orange County Convention Center) Session Time: 4:00 PM-5:30 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 4:00 PM 5:30 PM The Role of Maintenance Therapy for Multiple Myeloma in the Era of Novel Agents Thierry Facon 4:00 PM 5:30 PM When Does "Smoldering" Become an Open Flame? Evolving Diagnostic Criteria for Myeloma S. Vincent Rajkumar 4:00 PM 5:30 PM Novel Combination Approaches to Myeloma Sagar Lonial
  16. 16. Session Name: Hematology Course Directors' Workshop Session Location: Manatee Springs (Hyatt Regency Orlando) Session Time: 7:00 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:00 AM 9:00 AM Team-Based Learning Marc Kahn 7:00 AM 9:00 AM New Curricula in Medical Schools Jennifer Kesselheim 7:00 AM 9:00 AM LCME Transition Overview Marc Zumberg 7:00 AM 9:00 AM Flipping Classrooms Gowthami Arepally Session Name: 101. Red Cells and Erythropoiesis, Structure and Function, Metabolism, and Survival, Excluding Iron: Erythropoiesis Session Location: W414AB (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Conditional Knockout-First Gene Disruption of Dematin Causes Precipitous Loss of Erythrocyte Membrane Stability and Severe Hemolytic Anemia Athar Chishti 157 7:30 AM 9:00 AM Mirna Regulation of Blood Group AB0 Genes Romy Kronstein- Wiedemann 158 7:30 AM 9:00 AM Distinct Roles of TET Proteins in the Regulation of Normal and Disordered Human Erythropoiesis Xiuli An 159 7:30 AM 9:00 AM Pomalidomide Transcriptionally Reprograms Adult Erythroid Progenitors Independently of Ikaros Proteasomal Degradation Celgene Pomalyst Brian Dulmovits 160 7:30 AM 9:00 AM Mechanism Governing Heme Synthesis Reveals a GATA Factor-Heme Circuit That Controls Differentiation Emery Bresnick 161 7:30 AM 9:00 AM Staphylococcus Aureus Targets the Duffy Antigen Receptor for Chemokines (DARC) to Lyse Erythrocytes Yves Colin Aronovicz 162 Session Name: 601. Chromosomal Rearrangements and DNA Repair: Genomic Instability and Clonal Evolution In Hematopoietic Malignancy Session Location: W312 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Differential Regulation of c-Myc/Lin28 Discriminates Subclasses of Rearranged MLL Leukemia Lili Chen 163 7:30 AM 9:00 AM PI3Kdelta Inhibitors Increase Genomic Instability By Upregulating Aid Expression Mara Compagno 164 7:30 AM 9:00 AM Crispr-Cas9 Induced MLL-Rearrangements Cause Clonal Outgrowth in CD34+ Hematopoietic Stem Cells Dirk Heckl 165 7:30 AM 9:00 AM Exposure to Inflammatory Immune Responses As Driver of Clonal Evolution in Childhood Acute Lymphoblastic Leukemia Lars Klemm 166 7:30 AM 9:00 AM Kinetics of CLL Subclonal Architecture: Spontaneous Disease Progression or Treatment-Induced Selection? Ceri Oldreive 167 7:30 AM 9:00 AM Models of Pluripotent and Somatic Stem Cells to Study Tissue-Specific Sensitivities in Fanconi Anemia Timothy Chlon 168 Session Name: 617. Acute Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Novel Genetic Lesions in AML – Insight from Genome Wide Characterization Session Location: W110 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Rearrangements in Nucleoporin Family of Genes in Childhood Acute Myeloid Leukemia: A Report from Children Oncology Group and NCI/COG Target AML Initiative Fabiana Ostronoff 169 7:30 AM 9:00 AM Comprehensive Genomic and Transcript Profiling of CBL Gene in Childhood AML: A Report from Children's Oncology Group Studies AAML03P1, AAML0531 and COG/NCI Target AML Initiative Diana Chin 170 7:30 AM 9:00 AM Next Generation Sequencing Identifies a Novel Subset of Non-Down Syndrome Acute Megakaryoblastic Leukemia Characterized By Chimeric Transcripts Involving HOX Cluster Genes Jasmijn de Rooij 171 7:30 AM 9:00 AM Predictors of Early Death in Childhood Acute Promyelocytic Leukemia: Results of an International Retrospective Study Oussama Abla 172 7:30 AM 9:00 AM Significance of Peri-Transplant Dynamics of Minimal Residual Disease (MRD) in Adults with Acute Myeloid Leukemia (AML) in Morphological Remission Undergoing Myeloablative Allogeneic Hematopoietic Cell Transplantation Yi Zhou 173 7:30 AM 9:00 AM CSF3R Mutations Represent a Novel Therapeutic Target in Pediatric AML with a High Degree of Overlap with CEBPA Mutations: a Report from COG AAML0531 and COG/NCI Target AML Initiative Julia Maxson 174 Session Name: 621. Hodgkin Lymphoma: Biology, excluding Therapy: Biological Insights and Clinical Impact Session Location: W307 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Prediction of Primary Treatment Outcome Using Gene Expression Profiling of Pre-Treatment Biopsies Obtained from Childhood and Adolescent Hodgkin Lymphoma Patients Anja Mottok 175 7:30 AM 9:00 AM PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome Margaretha Roemer 176 7:30 AM 9:00 AM Disruption of Direct 3-Dimensional (3D) Telomere-TRF2 (Telomere Related Factor 2) Interaction Is a Hallmark of Primary Hodgkin (H) and Reed-Sternberg (RS) Cells Hans Knecht 177 7:30 AM 9:00 AM Analysis of the Genomic Heterogeneity in Hodgkin Lymphoma Using Next Generation Sequencing Juan F García 178 7:30 AM 9:00 AM DNA Methylation Differences in Twins Discordant for Adolescent/Young Adult Hodgkin Lymphoma Wendy Cozen 179 7:30 AM 9:00 AM TARC Predicts PET-Normalization and Event Free Surival in Relapsed/Refractory Hodgkin Lymphoma Patients Treated with Brentuximab Vedotin Seattle Genetics Adcetris Alison Moskowitz 180 Session Name: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Novel Immunotherapy Strategies in Lymphoma Session Location: W311 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Multicenter Phase II Study of Lenalidomide in Patients with Relapsed Adult T-Cell Leukemia- Lymphoma Celgene Revlimid Hiroshi Fujiwara 181 7:30 AM 9:00 AM A Phase 1 Study of Denintuzumab Mafodotin (SGN-CD19A) in Relapsed/Refactory B-Lineage Non- Hodgkin Lymphoma Seattle Genetics Denintuzumab Mafodotin Craig Moskowitz 182 7:30 AM 9:00 AM Sustained Remissions Following Chimeric Antigen Receptor Modified T Cells Directed Against CD19 (CTL019) in Patients with Relapsed or Refractory CD19+ Lymphomas Novartis CTL019 Stephen Schuster 183 7:30 AM 9:00 AM Anti-CD19 Chimeric Antigen Receptor-Modified T Cell Therapy for B Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia: Fludarabine and Cyclophosphamide Lymphodepletion Improves In Vivo Expansion and Persistence of CAR-T Cells and Clinical Outcomes Cameron Turtle 184 7:30 AM 9:00 AM Chimeric T Cells for Therapy of CD30+ Hodgkin and Non-Hodgkin Lymphomas Carlos Ramos 185 7:30 AM 9:00 AM Immunotherapy for Lymphoma Using T Cells Targeting Multiple Tumor Associated Antigens Ann Leen 186 2015 BioMedTracker ASH Planner Sunday December 6- Oral Presentations
  17. 17. 2015 BioMedTracker ASH Planner Sunday December 6- Oral Presentations Session Name: 653. Myeloma: Therapy, excluding Transplantation: Amyloidosis and Related Plasma Cell Disorders Session Location: Tangerine 2 (WF2) (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Phase I/II Trial of the Efficacy and Safety of Combination Therapy with Lenalidomide/Bortezomib/Dexamethasone (RVD) and Panobinostat in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma Novartis Farydak Jatin Shah 187 7:30 AM 9:00 AM Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis Suzanne Lentzsch 188 7:30 AM 9:00 AM Quadruplet Vs Sequential Triplet Induction Therapy Approaches to Maximise Response for Newly Diagnosed, Transplant Eligible, Myeloma Patients Charlotte Pawlyn 189 7:30 AM 9:00 AM Accurate Risk Stratification Identifies Patients with AL Amyloidosis Benefiting Most from Upfront Bortezomib Combinations: A Study of Treatment Outcomes in 984 Patients Giovanni Palladini 190 7:30 AM 9:00 AM Evaluation of Minimal Residual Disease (MRD) By Next Generation Sequencing (NGS) Is Highly Predictive of Progression Free Survival in the IFM/DFCI 2009 Trial Herve Avet-Loiseau 191 7:30 AM 9:00 AM A Prospective Phase II Study of Combination of Low Dose Lenalidomide and Dexamethasone for Patients with Newly Diagnosed POEMS Syndrome Dao-bin Zhou 192 Session Name: 732. Clinical Allogeneic Transplantation: Results: Matched Related, Unrelated, and Alternative Donor Allograft Outcomes for Myeloid and Lymphoid Malignancies Session Location: W304 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Outcome of Patients 65 Years and Older with Myelodysplastic Syndrome (MDS) Receiving Allogeneic Hematopoietic Stem Cell Transplantation Compared to Patients 55-64 Years of Age Ehab Atallah 193 7:30 AM 9:00 AM Survival after T-Cell Replete Haploidentical Related Donor Transplant Using Post-Transplant Cyclophosphamide Compared with Matched Unrelated Donor (MUD) Transplant for Lymphoid Malignancies Alberto Mussetti 194 7:30 AM 9:00 AM Children with Acute Leukemia Given Hematopoietic Stem Cell Transplantation (HSCT) from an HLA- Compatible Sibling, or an Unrelated Donor (UD) or an HLA-Haploidentical Relative after Alpha/Beta T-Cell Depletion Have a Comparable Outcome Alice Bertaina 195 7:30 AM 9:00 AM Comparison of Matched-Sibling Donors Versus Unrelated Donors in Allogeneic Stem Cell Transplantation (allo-SCT) for Primary Refractory Acute Myeloid Leukemia (PRF AML): A Report of 1041 Patients from the Acute Leukemia Working Party of the EBMT Eolia Brissot 196 7:30 AM 9:00 AM Reduced-Intensity Allogeneic Hematopoietic Cell Transplantation (allo-HCT) Provides Durable Progression-Free Survival (PFS) in a Subset of Diffuse Large B-Cell Lymphoma (DLBCL) Patients Relapsing after Autologous (auto-) HCT Timothy Fenske 197 7:30 AM 9:00 AM Allogeneic Stem Cell Transplantation for Relapsed / Refractory (R/R) Follicular Lymphoma (FL). a Joint Study Between the European Society for Blood and Marrow Transplantation (EBMT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) Anna Sureda 198 Session Name: 801. Gene Therapy and Transfer: Gene Therapy for Hemoglobinopathies and Inherited Bleeding Disorders Session Location: Tangerine 3 (WF3-4) (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Adeno-Associated Viral Vector Delivery of Optimized Human Factor VIII Achieves Therapeutic Factor VIII Levels in Non-Human Primates Xavier Anguela 199 7:30 AM 9:00 AM ZFN-Mediated Gene Targeting at the Albumin Locus in Liver Results in Therapeutic Levels of Human FIX in Mice and Non-Human Primates Michael Holmes 200 7:30 AM 9:00 AM Update of Results from the Northstar Study (HGB-204): A Phase 1/2 Study of Gene Therapy for Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex-Vivo with a Lentiviral Beta AT87Q-Globin Vector (LentiGlobin BB305 Drug Product) bluebird bio LentiGlobin Mark Walters 201 7:30 AM 9:00 AM Outcomes of Gene Therapy for Severe Sickle Disease and Beta-Thalassemia Major Via Transplantation of Autologous Hematopoietic Stem Cells Transduced Ex Vivo with a Lentiviral Beta AT87Q-Globin Vector bluebird bio LentiGlobin Marina Cavazzana 202 7:30 AM 9:00 AM Genome Editing of the Bcl11A Erythroid Specific Enhancer in Bone Marrow Derived Hematopoietic Stem and Progenitor Cells for the Treatment of Sickle Cell Disease Siyuan Tan 203 7:30 AM 9:00 AM Clinical-Scale Genome Editing of the Human BCL11A Erythroid Enhancer for Treatment of the Hemoglobinopathies Fyodor Urnov 204 Session Name: Anemia: When Something's Wrong with Iron Session Location: W230 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Iron Deficiency: New Insights into Diagnosis and Treatment Clara Camaschella 7:30 AM 9:00 AM Understanding Anemia of Chronic Disease Paula Fraenkel 7:30 AM 9:00 AM Diagnosis and Treatment of Sideroblastic Anemias: From Defective Heme Synthesis to Abnormal RNA Splicing Mario Cazzola Session Name: Guiding Hematologic Care with Genetic Testing Session Location: Hall D (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Using Genetic Diagnostics in Hemophilia and von Willebrand Disease Paula James 7:30 AM 9:00 AM Sickle Cell Trait Diagnosis: Clinical and Social Implications Rakhi Naik 7:30 AM 9:00 AM Using Red Blood Cell Genomics in Transfusion Medicine Jill Johnsen Session Name: Imaging and Treating the Clot: What's New? Session Location: Valencia BC (W415BC) (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Incidental Pulmonary Embolism: What’s the Clinician to do? Casey O'Connell 7:30 AM 9:00 AM Imaging New and Recurrent Thrombosis Menno Huisman 7:30 AM 9:00 AM Clot Lysis and Stenting Suresh Vedantham Session Name: Overcoming the Barrier of TP53 Dysfunction to Cure Blood Cancers Session Location: Hall E1 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Deconstructing p53 Transcriptional Networks in Tumor Suppression Laura Attardi 7:30 AM 9:00 AM Biology of TP53 Loss and Mutation Guillermina Lozano 7:30 AM 9:00 AM Circumventing TP53 Dysfunction: Targeting Cell Survival Pathways David Huang
  18. 18. 2015 BioMedTracker ASH Planner Sunday December 6- Oral Presentations Session Name: Palliative Care in Hematological Malignancies Session Location: W308 (Orange County Convention Center) Session Time: 7:30 AM-9:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 7:30 AM 9:00 AM Spanning the Canyon Between Stem Cell Transplantation and Palliative Care Eric Roeland 7:30 AM 9:00 AM When and Why Should Patients with Hematological Malignancies See a Palliative Care Specialist? Thomas LeBlanc 7:30 AM 9:00 AM Palliative Care in Pediatric Patients with Hematologic Malignancies Tammy Kang Session Name: 203. Lymphocytes, Lymphocyte Activation and Immunodeficiency, including HIV and Other Infections: Novel Immunodeficiencies and Natural Killer Cell Biology Session Location: W315 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Impairment of IL-17 Immunity to Candida and IFN-g Immunity to Mycobacterium in Humans with Bi-Allelic Rorc mutations Satoshi Okada 205 9:30 AM 11:00 AM Dominant NFKB1 Mutations Cause Antibody Deficiency and Autoinflammatory Episodes Emma Haapaniemi 206 9:30 AM 11:00 AM Microrna 29b Mediates Immune Evasion of Natural Killer Cells in Acute Myeloid Leukemia Steven Scoville 207 9:30 AM 11:00 AM Impact of Kindlin-3 in NK Cell-Mediated Anti-Tumor Cytotoxicity and Inflammatory Cytokine Production Nathan Schloemer 208 9:30 AM 11:00 AM mTORC1 Signaling and Metabolism Are Dynamically Regulated during Human NK Cell Maturation and in Adaptive NK Cell Responses to Viral Infection Cichocki Frank 209 9:30 AM 11:00 AM Modulation of Natural Killer Cell Activity in the Setting of Oncolytic Virotherapy and with a Chimeric Antigen Receptor Chen Xilin 210 Session Name: 321. Blood Coagulation and Fibrinolytic Factors: Coagulation Proteins and Blood Vessels Session Location: W314 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Bleeding Phenotype Observed in Murine Defect of VWF-Collagen 4 Interactions Veronica Flood 211 9:30 AM 11:00 AM A Targeted Photochemical Microfluidic Vascular Injury Model for in Vitro Thrombosis Studies: Usage in Heparin-Induced Thrombocytopenia (HIT) Ian Johnston 212 9:30 AM 11:00 AM The Role of Putative Phosphatidylserine-Interactive Residues of Tissue Factor on Its Coagulant Activity at the Cell Surface Shabbir Ansari 213 9:30 AM 11:00 AM Von Willebrand Factor Protects Factor VIII from Rapid Endocytosis Via LDL Receptor-Related Protein By Blocking the Initial Rate-Limiting Cell Surface Binding Step of Factor VIII Henriet Meems 214 9:30 AM 11:00 AM Clot Contraction-Mediated Erythrocyte Packing Is Significantly Altered in Sickle Cell Disease Hunter Strauss 215 9:30 AM 11:00 AM Coagulation Factor V Mediates Inhibition of Tissue Factor Signaling By Activated Protein C Hartmut Weiler 216 Session Name: 615. Acute Myeloid Leukemia: Commercially available Therapy, excluding Transplantation: New Approaches Using Older Drugs Session Location: W109 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM North American Leukemia‚ Intergroup Phase III Randomized Trial of Single Agent Clofarabine As Induction and Post-Remission Therapy‚ and Decitabine As Maintenance Therapy in Newly- Diagnosed Acute Myeloid Leukemia in Older Adults (Age ≥60 Years): A Trial of the ECOG-ACRIN Cancer Research Group (E2906) James Foran 217 9:30 AM 11:00 AM Clofarabine-Based Consolidation Improves Relapse-Free Survival of Younger Adults with Non- Favorable Acute Myeloid Leukemia (AML) in First Remission: Results of the Randomized ALFA- 0702/Clara Study (NCT 00932412) Xavier Thomas 218 9:30 AM 11:00 AM Results of a Phase III Trial Including Arsenic Trioxide Consolidation for Pediatric Patients with Acute Promyelocytic Leukemia (APL): A Report from the Children's Oncology Group Study AAML0631 Matthew Kutny 219 9:30 AM 11:00 AM Tamibarotene Compared to All-Trans Retinoic Acid (ATRA) As Add-on to Arsenic Trioxide (ATO) in Subjects with Relapsed Acute Promyelocytic Leukemia (APL) Jianxiang Wang 220 9:30 AM 11:00 AM A Comparison of 1 or 2 Courses of High Dose Cytarabine As Consolidation in Younger Patients with AML: First Results of the UK NCRI AML17 Trial Nigel Russell 221 9:30 AM 11:00 AM Randomized Comparison of Intermediate-Dose Cytarabine Plus Mitoxantrone (IMA) Versus Standard-Dose Cytarabine Plus Daunorubicin (DA) for Induction Therapy in AML Patients >60 Years. Results from the SAL 60+ Trial Christoph Röllig 222 Session Name: 617. Acute Myeloid Leukemia: Biology, Cytogenetics and Molecular Markers in Diagnosis and Prognosis: Novel Molecular Markers for the Detection of Clonal Hematopoiesis and Minimal Residual Disease Session Location: W110 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM On the Origins of AML Relapse Liran Shlush 223 9:30 AM 11:00 AM Characteristics and Prognosis of AML Patients with or without a History of Clonal Hematopoiesis Felicitas Thol 224 9:30 AM 11:00 AM High-Sensitivity Genomic Minimal Residual Disease Detection Reveals Multiclonal Hematopoiesis and Is Associated with Survival in Adult AML Brian Parkin 225 9:30 AM 11:00 AM Monitoring of Minimal Residual Disease (MRD) of DNMT3A Mutations (DNMT3Amut) in Acute Myeloid Leukemia (AML): A Study of the AML Study Group (AMLSG) Verena Gaidzik 226 9:30 AM 11:00 AM Clinical Relevance of Minimal Residual Disease Monitoring in NPM1 Mutated AML: A Study of the AML Study Group (AMLSG) Silke Kapp-Schwoerer 227 9:30 AM 11:00 AM Clinical Impact of Minimal Residual Disease (MRD) Monitoring in AML with PML-Rara, CBFB- MYH11, and RUNX1-RUNX1T1: A Study on 600 Patients Torsten Haferlach 228 Session Name: Challenges in Hemophilia Care Session Location: W307 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Emerging Genetic and Pharmacologic Therapies for Controlling Hemostasis Paul Monahan 9:30 AM 11:00 AM The Long and Short of It: Using the New Factor Products Amy Dunn 9:30 AM 11:00 AM Managing Older Patients with Hemophilia Suman Sood Session Name: Hemophagocytic Lymphohistiocytosis in Adults Session Location: Hall E2 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Focus on Presentation and Diagnosis of Hemophagocytic Lymphohistiocytosis in Adults Nancy Berliner 9:30 AM 11:00 AM Pathophysiology and Epidemiology of Hemophagocytic Lymphohistiocytosis Carl Allen 9:30 AM 11:00 AM Treatment of Hemophagocytic Lymphohistiocytosis in Adults Paul La Rosée
  19. 19. 2015 BioMedTracker ASH Planner Sunday December 6- Oral Presentations Session Name: New Approaches in Chronic Lymphocytic Leukemia and Prolymphocytic Leukemia Session Location: Tangerine 2 (WF2) (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Management of Prolymphocytic Leukemia Claire Dearden 9:30 AM 11:00 AM Patterns of Resistance to B-Cell Receptor Pathway Antagonists in Chronic Lymphocytic Leukemia and Strategies for Management Jennifer Woyach 9:30 AM 11:00 AM Emerging Prognostic Markers in Chronic Lymphocytic Leukemia and their Impact on Treatment Strategies Stephan Stilgenbauer Session Name: Optimizing Transfusion Therapy (AABB Session) Session Location: W308 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Red Blood Cell Transfusion Goals in Hematologic Disease Brenda Grossman 9:30 AM 11:00 AM Implementing a Blood Management Program to Optimize Transfusion Utilization William Savage 9:30 AM 11:00 AM Platelet Transfusion Goals in Hematologic Disease Cassandra Josephson Session Name: Patient-Reported Outcomes in Hematology Session Location: W230 (Orange County Convention Center) Session Time: 9:30 AM-11:00 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:00 AM Patient-Reported Outcomes and Drug Development Catherine Acquadro 9:30 AM 11:00 AM The Science Behind Developing a Patient-Reported Outcome Measure David Cella 9:30 AM 11:00 AM Patient-Reported Outcomes in Clinical Practice Julie Panepinto 9:30 AM 11:00 AM Patient-Reported Outcomes and Drug Development Virginia Kwitkowski Session Name: 702. Experimental Transplantation: Immune Function, GVHD, and Graft-versus-Tumor Effects: Shifting the Balance Between GVH, GVT, and Post-transplant Immunity Session Location: W414AB (Orange County Convention Center) Session Time: 9:30 AM-11:15 AM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 9:30 AM 11:15 AM Donor T Cells Intrinsic Responses to Damps Regulated By Siglec-G-CD24 Axis Mitigate Gvhd but Maintain GVL in Experimental BMT Model Tomomi Toubai 229 9:30 AM 11:15 AM R-spondin1 Promotes Paneth Cell Growth, Maintains Intestinal Microbial Ecology, and Ameliorates GvHD Eiko Hayase 230 9:30 AM 11:15 AM IL-33/ST2 Triggering of IL-9-Secreting T Cells Alters the Balance of Fatal Immunity and Tumor Immunity Abdulraouf Ramadan 231 9:30 AM 11:15 AM Trispecific Killer Engagers (TriKEs) that contain IL-15 to make NK cells antigen specific and to sustain their persistence and expansion Jeffrey Miller 232 9:30 AM 11:15 AM Programming of Donor T Cells Using Allogeneic Delta-like Ligand 4-Positive Dendritic Cells to Reduce Gvhd but Retain GVL Activity Lijun Meng 233 9:30 AM 11:15 AM Pharmacological Inhibition of Hsp90 Destabilizes the Histone Methyltransferase Ezh2 in Alloreactive T Cells and Reduces Graft-Versus-Host Disease While Retaining Anti-Leukemic Effects in Mice Qingrong Huang 234 9:30 AM 11:15 AM Production of BMP4 By Endothelial Cells Is Crucial for Endogenous Thymic Regeneration Jarrod Dudakov 637 Session Name: Continuing Conversations with the Speakers on Harnessing T cells in Therapy of Hematologic Malignancy Session Location: W303 (Orange County Convention Center) Session Time: 11:15 AM-12:15 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 11:15 AM 12:15 PM Speaker Michel Sadelain 11:15 AM 12:15 PM Speaker Dirk Busch 11:15 AM 12:15 PM Speaker Crystal Mackall Session Name: Continuing Conversations with the Speakers on Send in the Clones: Stem Cell Succession, Replicative Stress and Somatic Reversion Session Location: Lecture Hall W300 (Orange County Convention Center) Session Time: 11:15 AM-12:15 PM Start Time End Time Presentation Title Company Drug Presenter Presentation ID 11:15 AM 12:15 PM Speaker Michael Milsom 11:15 AM 12:15 PM Speaker Fernando Camargo 11:15 AM 12:15 PM Speaker Marjolijn Jongmans

×